<qa>  What is the name of the kinase used to evaluate tumor tissue expression of endI. To evaluate tumor tissue expression of endoglin CD105, transforming growth factor, beta receptor II TGFBR2, activin A receptor type II-like 1 ACVRL1 and transforming growth factor, beta receptor 1 TGFBR1 kinase from pre- and post-treatment tissue samples in order to determine whether CD105 and stem cell activation occurs after exposure to anti-vascular endothelial growth factor VEGF therapy as predicted by laboratory models, and whether exposure to anti-endoglin monoclonal antibody TRC105 affects these changes. 